Compare AAP & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAP | CLDX |
|---|---|---|
| Founded | 1929 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.0B |
| IPO Year | 2002 | 1995 |
| Metric | AAP | CLDX |
|---|---|---|
| Price | $42.05 | $29.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 25 | 15 |
| Target Price | $49.95 | ★ $63.07 |
| AVG Volume (30 Days) | 1.6M | ★ 2.0M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 113.01 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $8,601,000,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $19.74 |
| Revenue Next Year | $2.25 | $438.11 |
| P/E Ratio | $32.37 | ★ N/A |
| Revenue Growth | N/A | ★ 87.78 |
| 52 Week Low | $37.89 | $22.10 |
| 52 Week High | $65.20 | $45.14 |
| Indicator | AAP | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 30.57 |
| Support Level | $40.94 | $28.82 |
| Resistance Level | $44.92 | $31.80 |
| Average True Range (ATR) | 1.40 | 1.90 |
| MACD | 0.56 | -0.20 |
| Stochastic Oscillator | 72.53 | 12.44 |
Advance Auto Parts is a leading auto-parts retailer in North America with more than 4,000 store and branch locations. About half of the firm's sales are geared toward the professional channel, with the remaining sales in the do-it-yourself market. Through its vast store footprint and distribution network, Advance manages thousands of stock-keeping units for various vehicle makes and models. The retailer primarily competes on inventory availability and service speed, making the operating efficiency of its hub-and-spoke distribution model critical to meeting customer needs.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.